|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.2 USD | +0.37% |
|
+4.31% | +20.34% |
| Apr. 26 | Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141 | MT |
| Apr. 26 | Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128 | MT |
10:08 ET -- Merck & Co. is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The drugmaker won Food and Drug Administration approval for Winrevair to treat pulmonary arterial hypertension, a potentially fatal lung disease. Merck shares rise 4.6% to $131.30. Dow Jones & Co. owns Factiva. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
03-27-24 1024ET
| 1st Jan change | Capi. | |
|---|---|---|
| +20.34% | 332B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B | |
| -11.77% | 144B |
MERCK & CO., INC. 
